Literature DB >> 26246763

A Brief History of the Development of Diabetes Medications.

John R White.   

Abstract

This article provides an overview of the development of insulins, oral agents, and noninsulin injectable agents used in the management of hyperglycemia in patients with diabetes. It also briefly reviews the pharmacological impact and salient side effects of these medications.

Entities:  

Year:  2014        PMID： 26246763      PMCID： PMC4522877          DOI： 10.2337/diaspect.27.2.82

Source DB:  PubMed          Journal:  Diabetes Spectr        ISSN： 1040-9165


  11 in total

Review 1.  Thiazolidinediones: the case for early use.

Authors:  David M Kendall
Journal:  Diabetes Care       Date:  2006-01       Impact factor: 19.112

Review 2.  The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.

Authors:  Vanita R Aroda; Robert Ratner
Journal:  Diabetes Metab Res Rev       Date:  2011-09       Impact factor: 4.876

3.  Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

Authors:  M Monami; C Nardini; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2013-12-29       Impact factor: 6.577

4.  Progressive retinopathy with improved control in diabetic dwarfism (Mauriac's syndrome).

Authors:  D Daneman; A L Drash; L A Lobes; D J Becker; L M Baker; L B Travis
Journal:  Diabetes Care       Date:  1981 May-Jun       Impact factor: 19.112

5.  Sulfonylureas: background and development of the field.

Authors:  R Levine
Journal:  Diabetes Care       Date:  1984 May-Jun       Impact factor: 19.112

6.  Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects.

Authors:  D M Nathan; E Schreiber; H Fogel; S Mojsov; J F Habener
Journal:  Diabetes Care       Date:  1992-02       Impact factor: 19.112

7.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

Authors:  M Gutniak; C Orskov; J J Holst; B Ahrén; S Efendic
Journal:  N Engl J Med       Date:  1992-05-14       Impact factor: 91.245

Review 8.  Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Authors:  Joshua J Neumiller
Journal:  J Am Pharm Assoc (2003)       Date:  2009 Sep-Oct

Review 9.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

10.  History of current non-insulin medications for diabetes mellitus.

Authors:  Celeste C L Quianzon; Issam E Cheikh
Journal:  J Community Hosp Intern Med Perspect       Date:  2012-10-15
View more
  35 in total

Review 1.  Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar.

Authors:  Tanya Wilcox; Christophe De Block; Arthur Z Schwartzbard; Jonathan D Newman
Journal:  J Am Coll Cardiol       Date:  2020-04-28       Impact factor: 24.094

Review 2.  New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy.

Authors:  Mercy Saw; Vincent W Wong; I-Van Ho; Gerald Liew
Journal:  Eye (Lond)       Date:  2019-06-21       Impact factor: 3.775

Review 3.  Cardiovascular Outcome Trials with Glucose-Lowering Drugs.

Authors:  Tina K Thethi; Anika Bilal; Richard E Pratley
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

Review 4.  Auditory and Vestibular Side Effects of FDA-Approved Drugs for Diabetes.

Authors:  Robert M DiSogra; Jerry Meece
Journal:  Semin Hear       Date:  2019-10-09

5.  Chemically Precise Glycoengineering Improves Human Insulin.

Authors:  Xiaoyang Guan; Patrick K Chaffey; Xiuli Wei; Daniel R Gulbranson; Yuan Ruan; Xinfeng Wang; Yaohao Li; Yan Ouyang; Liqun Chen; Chen Zeng; Theo N Koelsch; Amy H Tran; Wei Liang; Jingshi Shen; Zhongping Tan
Journal:  ACS Chem Biol       Date:  2017-12-01       Impact factor: 5.100

Review 6.  Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?

Authors:  Laura N McEwen; Sarah Stark Casagrande; Shihchen Kuo; William H Herman
Journal:  Curr Diab Rep       Date:  2017-09       Impact factor: 4.810

7.  Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes.

Authors:  HoJin Shin; Sebastian Schneeweiss; Robert J Glynn; Elisabetta Patorno
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-01-17       Impact factor: 2.890

8.  Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005-2007 and 2015-2017.

Authors:  Xilin Zhou; Sundar S Shrestha; Hui Shao; Ping Zhang
Journal:  Diabetes Care       Date:  2020-07-31       Impact factor: 19.112

9.  Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

Authors:  Takayoshi Kanie; Atsushi Mizuno; Yoshimitsu Takaoka; Takahiro Suzuki; Daisuke Yoneoka; Yuri Nishikawa; Wilson Wai San Tam; Jakub Morze; Andrzej Rynkiewicz; Yiqiao Xin; Olivia Wu; Rui Providencia; Joey Sw Kwong
Journal:  Cochrane Database Syst Rev       Date:  2021-10-25

Review 10.  Fat, Sugar or Gut Microbiota in Reducing Cardiometabolic Risk: Does Diet Type Really Matter?

Authors:  Katarzyna Nabrdalik; Katarzyna Krzyżak; Weronika Hajzler; Karolina Drożdż; Hanna Kwiendacz; Janusz Gumprecht; Gregory Y H Lip
Journal:  Nutrients       Date:  2021-02-16       Impact factor: 5.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.